Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 3/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.51 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.44 |
| ▸ | HRH1 | P35367 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5178508 | 1.00 | CHRM2 (0.51) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL27766210 | 0.93 | CHRM2 (0.44) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL5179277 | 0.89 | CHRM2 (0.48) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL5179612 | 0.89 | CHRM2 (0.48) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL5179279 | 0.89 | CHRM2 (0.48) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL6934593 | 0.87 | CHRM2 (0.56) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL6934595 | 0.87 | CHRM2 (0.56) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL13196106 | 0.86 | CHRM2 (0.48) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL19212492 | 0.86 | CHRM2 (0.48) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL19212477 | 0.86 | CHRM2 (0.48) | CHRM2CHRM1CHRM5CHRM3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545024-B1 | PROCESS FOR PREPARATION OF 3-(2-HYDROXY-5-SUBSTITUTED PHENYL)-3-PHENYLPROPYLAMINES, INTERMEDIATES FOR MAKING HYDROXYTOLTERODINE AND FESOTERODINE | LEK PHARMACEUTICALS (SI) | 2016-08-03 | — | — | EP | disclosed |
| US-9315450-B2 | Desfesoterodine salts | RATIOPHARM GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| US-9315450-B2 | Desfesoterodine salts | RATIOPHARM GMBH (DE) | 2016-04-19 | — | — | US | disclosed |
| EP-2760822-B1 | DESFESOTERODINE SALTS | RATIOPHARM GMBH (DE) | 2016-03-23 | — | — | EP | disclosed |
| US-20150152044-A1 | DESFESOTERODINE SALTS | RATIOPHARM GMBH (DE) | 2015-06-04 | — | — | US | disclosed |
| US-20150152044-A1 | DESFESOTERODINE SALTS | RATIOPHARM GMBH (DE) | 2015-06-04 | — | — | US | disclosed |
| WO-2013188829-A1 | DESFESOTERODINE SALTS | RATIOPHARM GMBH (DE) | 2013-12-19 | — | — | WO | disclosed |
| US-20130197082-A1 | SHORT SYNTHESIS OF TOLTERODINE, INTERMEDIATES AND METABOLITES | LEK PHARMACEUTICALS D.D. (SI) | 2013-08-01 | — | — | US | disclosed |
| WO-2012098560-A2 | PROCESS FOR THE PREPARATION OF MUSCARINIC RECEPTOR ANTAGONIST | MSN LABORATORIES LIMITED (IN) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012098560-A2 | PROCESS FOR THE PREPARATION OF MUSCARINIC RECEPTOR ANTAGONIST | MSN LABORATORIES LIMITED (IN) | 2012-07-26 | — | — | WO | disclosed |
| US-20070265303-A1 | Amine derivatives | PFIZER LIMITED | 2007-11-15 | — | — | US | disclosed |
| US-20070265303-A1 | Amine derivatives | PFIZER LIMITED | 2007-11-15 | — | — | US | disclosed |
| US-20070265303-A1 | Amine derivatives | PFIZER LIMITED | 2007-11-15 | — | — | US | disclosed |
| WO-2007107828-A2 | AMINE DERIVATIVES | PFIZER LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107828-A2 | AMINE DERIVATIVES | PFIZER LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| EP-1019358-B2 | 3,3-DIARYLPROPYLAMINES , THEIR USE AND PREPARATION | PFIZER HEALTH AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| EP-1019358-B1 | 3,3-DIARYLPROPYLAMINES , THEIR USE AND PREPARATION | PHARMACIA AB (SE) | 2003-05-07 | — | — | EP | disclosed |
| US-6313132-B1 | FOR THERAPY OF URINARY INCONTINENCE, ACETYLCHOLINE-MEDIATED DISORDER | PHARMACIA AB (SE) | 2001-11-06 | — | — | US | disclosed |
| EP-1019358-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | Pharmacia & Upjohn AB (SE) | 2000-07-19 | — | — | EP | disclosed |
| WO-1998043942-A1 | NOVEL COMPOUNDS, THEIR USE AND PREPARATION | PHARMACIA & UPJOHN AB (SE) | 1998-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130197082-A1 | SHORT SYNTHESIS OF TOLTERODINE, INTERMEDIATES AND METABOLITES | COMT, UGT1A7, PAH | CHRM2 867/4885CHRM1 1092/4885CHRM5 1945/4885 |
| US-20150152044-A1 | DESFESOTERODINE SALTS | TES, SYMPK, ADRB3 | CHRM2 223/4885CHRM1 433/4885CHRM5 579/4885 |
| US-20070265303-A1 | Amine derivatives | HNMT, HRH4, CMA1 | CHRM2 142/4885CHRM1 87/4885CHRM5 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.